JLE

Epileptic Disorders

MENU

Neuronal ceroid lipofuscinoses Volume 18, supplément 2, September 2016

  • [Ahtiainen et al., 2006] Ahtiainen L., Luiro K., Kauppi M., Tyynela J., Kopra O., Jalanko A. Palmitoyl protein thioesterase 1 (PPT1) deficiency causes endocytic defects connected to abnormal saposin processing. Exp Cell Res. 2006;312:1540-1553.
  • [Anderson et al., 2005] Anderson G., Smith V.V., Malone M., Sebire N.J. Blood film examination for vacuolated lymphocytes in the diagnosis of metabolic disorders; retrospective experience of more than 2,500 cases from a single centre. J Clin Pathol. 2005;58:1305-1310.
  • [Autti et al., 1992] Autti T., Raininko R., Launes J., Nuutila A., Santavuori P. Jansky-Bielschowsky variant disease: CT, MRI, and SPECT findings. Pediatr Neurol. 1992;8:121-126.
  • [Batten, 1903] Batten F.E. Cerebral degeneration with symmetrical changes in the maculae in two members of a family. Trans Ophthalmol Soc UK. 1903;23:386-390.
  • [Bielschowsky, 1913] Bielschowsky M. Über spätinfantile familiäre amaurotische Idiotie mit Kleinhirnsymptonen. Dtsch Z Nervenheilkd. 1913;50:7-29.
  • [Bras et al., 2012] Bras J., Verloes A., Schneider S.A., Mole S.E., Guerreiro R.J. Mutation of the parkinsonism gene A2 causes neuronal ceroid-lipofuscinosis. Hum Mol Genet. 2012;21:2646-2650. ATP13
  • [Chang et al., 2008] Chang M., Cooper J.D., Sleat D.E. Intraventricular enzyme replacement improves disease phenotypes in a mouse model of late infantile neuronal ceroid lipofuscinosis. Mol Ther. 2008;16:649-656.
  • [Chattopadhyay et al., 2002] Chattopadhyay S., Kriscenski-Perry E., Wenger D.A., Pearce D.A. An autoantibody to GAD65 in sera of patients with juvenile neuronal ceroid lipofuscinoses. Neurology. 2002;59:1816-1817.
  • [Craiu et al., 2015] Craiu D., Dragostin O., Dica A. Rett-like onset in late-infantile neuronal ceroid lipofuscinosis (CLN7) caused by compound heterozy ous mutation in the gene and review of the literature data on clinical onset signs. Eur J Paediatr Neurol. 2015;19:78-86. MFSD8
  • [Eksandh et al., 2000] Eksandh L.B., Ponjavic V.B., Munroe P.B. Full-field ERG in patients with Batten/Spielmeyer-Vogt disease caused by mutations in the gene. Ophthalmic Genet. 2000;21:69-77. CLN3
  • [Elleder et al., 1997] Elleder M., Franc J., Kraus J., Nevsimalova S., Sixtova K., Zeman J. Neuronal ceroid lipofuscinosis in the Czech Republic: analysis of 57 cases. Report of the “Prague NCL group”. Eur J Paediatr Neurol. 1997;1:109-114.
  • [Goebel and Wisniewski, 2004] Goebel H.H., Wisniewski K.E. Current state of clinical and morphological features in human NCL. Brain Pathol. 2004;14:61-69.
  • [Golabek et al., 2000] Golabek A.A., Kida E., Walus M., Kaczmarski W., Michalewski M., Wisniewski K.E. CLN3 protein regulates lysosomal pH, and alters intracellular processing of Alzheimer's amyloid-beta protein precursor and cathepsin D in human cells. Mol Genet Metab. 2000;70:203-213.
  • [Greaves and Chamberlain, 2007] Greaves J., Chamberlain L.H. Palmitoylation-dependent protein sorting. J Cell Biol. 2007;176:249-254.
  • [Guillaume et al., 2008] Guillaume D.J., Huhn S.L., Selden N.R., Steiner R.D. Cellular therapy for childhood neurodegenerative disease. Part I: rationale and preclinical studies. Neurosurg Focus. 2008;24:E22.
  • [Haltia et al., 1973a] Haltia M., Rapola J., Santavuori P. Infantile type of so-called neuronal ceroid-lipofuscinosis. Histological and electron microscopic studies. Acta Neuropathol. 1973;26:157-170.
  • [Haltia et al., 1973b] Haltia M., Rapola J., Santavuori P., Keranen A. Infantile type of so-called neuronal ceroid-lipofuscinosis 2. Morphological and biochemical studies. J Neurol Sci. 1973;18:269-285.
  • [Heine et al., 2004] Heine C., Koch B., Storch S., Kohlschutter A., Palmer D.N., Braulke T. Defective endoplasmic reticulum-resident membrane protein CLN6 affects lysosomal degradation of endocytosed arylsulfatase A. J Biol Chem. 2004;279:22347-22352.
  • [Hobert and Dawson, 2007] Hobert J.A., Dawson G. A novel role of the Batten disease gene , association with BMP synthesis. Biochem Biophys Res Commun. 2007;358:111-116. CLN3
  • [Holopainen et al., 2001] Holopainen J.M., Saarikoski J., Kinnunen P.K., Jarvela I. Elevated lysosomal pH in neuronal ceroid lipofuscinoses (NCLs). Eur J Biochem. 2001;268:5851-5856.
  • [Jalanko and Braulke, 2009] Jalanko A., Braulke T. Neuronal ceroid lipofuscinoses. Biochim Biophys Acta. 2009;1793:697-709.
  • [Janský, 1908] Janský J. Dosud nepopsaný pripad familiárniamaurotické idiotie komplikované s hypoplasii mozeckovou. Sb Lek. 1908;13:165-196.
  • [Kitzmuller et al., 2008] Kitzmuller C., Haines R.L., Codlin S., Cutler D.F., Mole S.E. A function retained by the common mutant CLN3 protein is responsible for the late onset of juvenile neuronal ceroid lipofuscinosis. Hum Mol Genet. 2008;17:303-312.
  • [Kousi et al., 2009] Kousi M., Siintola E., Dvorakova L. Mutations in are a common cause of variant late-infantile neuronal ceroid lipofuscinosis. Brain. 2009;132:810-819. CLN7/MFSD8
  • [Kufs, 1925] Kufs H. Über eine Spätform der amaurotischen Idiotie und ihre heredofamiliären Grundlagen. Z Gesamte Neurol Psychiatr. 1925;95:168-188.
  • [Kyttala et al., 2006] Kyttala A., Lahtinen U., Braulke T., Hofmann S.L. Functional biology of the neuronal ceroid lipofuscinoses (NCL) proteins. Biochim Biophys Acta. 2006;1762:920-933.
  • [Lake and Hall, 1993] Lake B.D., Hall N.A. Immunolocalization studies of subunit c in late-infantile and juvenile Batten disease. J Inherit Metab Dis. 1993;16:263-266.
  • [Levin et al., 2014] Levin S.W., Baker E.H., Zein W.M. Oral cysteamine bitartrate and N-acetylcysteine for patients with infantile neuronal ceroid lipofuscinosis: a pilot study. Lancet Neurol. 2014;13:777-787.
  • [Lu and Hofmann, 2006] Lu J.Y., Hofmann S.L. Inefficient cleavage of palmitoyl-protein thioesterase (PPT) substrates by aminothiols: implications for treatment of infantile neuronal ceroid lipofuscinosis. J Inherit Metab Dis. 2006;29:119-126.
  • [Lu et al., 2010] Lu J.Y., Hu J., Hofmann S.L. Human recombinant palmitoyl-protein thioesterase-1 (PPT1) for preclinical evaluation of enzyme replacement therapy for infantile neuronal ceroid lipofuscinosis. Mol Genet Metab. 2010;99:374-378.
  • [Margraf et al., 1999] Margraf L.R., Boriack R.L., Routheut A.A. Tissue expression and subcellular localization of CLN3, the Batten disease protein. Mol Genet Metab. 1999;66:283-289.
  • [Marshall et al., 2005] Marshall F.J., de Blieck E.A., Mink J.W. A clinical rating scale for Batten disease: reliable and relevant for clinical trials. Neurology. 2005;65:275-279.
  • [Minassian et al., 2016] Minassian B.A., Striano P., Avanzini G. Progressive Myoclonus Epilepsies: State-of-the-Art. Epileptic Disord. 2016;18:S1-S158. Suppl. 2
  • [Mink, 2010] Mink J.W. Neuronal ceroid lipofuscinoses (Batten's disease). American Academy of Neurology Annual Meeting. 2010.
  • [Mitchison et al., 1998] Mitchison H.M., Hofmann S.L., Becerra C.H. Mutations in the palmitoyl-protein thioesterase gene (PPT; CLN1) causing juvenile neuronal ceroid lipofuscinosis with granular osmiophilic deposits. Hum Mol Genet. 1998;7:291-297.
  • [Mole, 2014] Mole S.E. Development of new treatments for Batten disease. Lancet Neurol. 2014;13:749-751.
  • [Mole and Williams, 2013] Mole SE, Williams RE. Neuronal Ceroid-Lipofuscinoses. In: Pagon RA, Adam MP, Ardinger HH, Wallace SE, Amemiya A, Bean LJH, Bird TD, Fong CT, Mefford HC, Smith RJH, Stephens K, (Editors). GeneReviews® [Internet]. Seattle (WA). 2001 Oct 10 [updated 2013 Aug 1].
  • [Mole and Cotman, 2015] Mole S.E., Cotman S.L. Genetics of the neuronal ceroid lipofuscinoses (Batten disease). Biochim Biophys Acta. 2015;1852:2237-2241.
  • [Mole et al., 2005] Mole S.E., Williams R.E., Goebel H.H. Correlations between genotype, ultrastructural morphology and clinical phenotype in the neuronal ceroid lipofuscinoses. Neurogenetics. 2005;6:107-126.
  • [Mole et al., 2011] Mole S., Williams R., Goebel H. The neuronal ceroid lipofuscinoses (Batten disease). Oxford: Oxford University Press; 2011. 2nd ed
  • [Munroe et al., 1997] Munroe P.B., Mitchison H.M., O’Rawe A.M. Spectrum of mutations in the Batten disease gene, CLN3. Am J Hum Genet. 1997;61:310-316.
  • [Narayan et al., 2006] Narayan S.B., Rakheja D., Tan L., Pastor J.V., Bennett M.J. CLN3 P the Batten's disease protein, is a novel palmitoyl-protein delta-9 desaturase. Ann Neurol. 2006;60:570-577.
  • [Passini et al., 2006] Passini M.A., Dodge J.C., Bu J. Intracranial delivery of CLN2 reduces brain pathology in a mouse model of classical late infantile neuronal ceroid lipofuscinosis. J Neurosci. 2006;26:1334-1342.
  • [Pearce et al., 2004] Pearce D.A., Atkinson M., Tagle D.A. Glutamic acid decarboxylase autoimmunity in Batten disease and other disorders. Neurology. 2004;63:2001-2005.
  • [Phillips et al., 2005] Phillips S.N., Benedict J.W., Weimer J.M., Pearce D.A. CLN3, the protein associated with Batten disease: structure, function and localization. J Neurosci Res. 2005;79:573-583.
  • [Puranam et al., 1999] Puranam K.L., Guo W.X., Qian W.H., Nikbakht K., Boustany R.M. CLN3 defines a novel antiapoptotic pathway operative in neurodegeneration and mediated by ceramide. Mol Genet Metab. 1999;66:294-308.
  • [Ramadan et al., 2007] Ramadan H., Al-Din A.S., Ismail A. Adult neuronal ceroid lipofuscinosis caused by deficiency in palmitoyl protein thioesterase 1. Neurology. 2007;68:387-393.
  • [Ramirez-Montealegre and Pearce, 2005] Ramirez-Montealegre D., Pearce D.A. Defective lysosomal arginine transport in juvenile Batten disease. Hum Mol Genet. 2005;14:3759-3773.
  • [Ranta and Lehesjoki, 2000] Ranta S., Lehesjoki A.E. Northern epilepsy, a new member of the NCL family. Neurol Sci. 2000;21:S43-S47.
  • [Rawlings and Barrett, 1999] Rawlings N.D., Barrett A.J. Tripeptidyl-peptidase I is apparently the CLN2 protein absent in classical late-infantile neuronal ceroid lipofuscinosis. Biochim Biophys Acta. 1999;1429:496-500.
  • [Riikonen et al., 2000] Riikonen R., Vanhanen S.L., Tyynela J., Santavuori P., Turpeinen U. CSF insulin-like growth factor-1 in infantile neuronal ceroid lipofuscinosis. Neurology. 2000;54:1828-1832.
  • [Santavuori et al., 1973] Santavuori P., Haltia M., Rapola J., Raitta C. Infantile type of so-called neuronal ceroid-lipofuscinosis 1. A clinical study of 15 patients. J Neurol Sci. 1973;18:257-267.
  • [Santavuori et al., 1991] Santavuori P., Rapola J., Nuutila A. The spectrum of Jansky-Bielschowsky disease. Neuropediatrics. 1991;22:92-96.
  • [Santavuori et al., 2000] Santavuori P., Lauronen L., Kirveskari K., Aberg L., Sainio K. Neuronal ceroid lipofuscinoses in childhood. Suppl Clin Neurophysiol. 2000;53:443-451.
  • [Schulz et al., 2004] Schulz A., Dhar S., Rylova S. Impaired cell adhesion and apoptosis in a novel CLN9 Batten disease variant. Ann Neurol. 2004;56:342-350.
  • [Schulz et al., 2013] Schulz A., Kohlschütter A., Mink J., Simonati A., Williams R. NCL diseases – clinical perspectives. Biochim Biophys Acta. 2013;1832:1801-1803.
  • [Seitz et al., 1998] Seitz D., Grodd W., Schwab A., Seeger U., Klose U., Nagele T. MR imaging and localized proton MR spectroscopy in late infantile neuronal ceroid lipofuscinosis. Am J Neuroradiol. 1998;19:1373-1377.
  • [Selden et al., 2013] Selden N.R., Al-Uzri A., Huhn S.L. Central nervous system stem cell transplantation for children with neuronal ceroid lipofuscinosis. J Neurosurg Pediatr. 2013;11:643-652.
  • [Sharp et al., 2003] Sharp J.D., Wheeler R.B., Parker K.A., Gardiner R.M., Williams R.E., Mole S.E. Spectrum of mutations in variant late infantile neuronal ceroid lipofuscinosis. Hum Mutat. 2003;22:35-42. CLN6
  • [Siintola et al., 2006] Siintola E., Partanen S., Stromme P. Cathepsin D deficiency underlies congenital human neuronal ceroid-lipofuscinosis. Brain. 2006;129:1438-1445.
  • [Sleat et al., 1999] Sleat D.E., Gin R.M., Sohar I. Mutational analysis of the defective protease in classic late-infantile neuronal ceroid lipofuscinosis, a neurodegenerative lysosomal storage disorder. Am J Hum Genet. 1999;64:1511-1523.
  • [Sleat et al., 2005] Sleat D.E., Lackland H., Wang Y. The human brain mannose 6-phosphate glycoproteome: a complex mixture composed of multiple isoforms of many soluble lysosomal proteins. Proteomics. 2005;5:1520-1532.
  • [Smith et al., 2012] Smith K.R., Damiano J., Franceschetti S. Strikingly different clinicopathological phenotypes determined by progranulin-mutation dosage. Am J Hum Genet. 2012;90:1102-1107.
  • [Smith et al., 2013] Smith K.R., Dahl H.H., Canafoglia L. Cathepsin F mutations cause type B Kufs disease, an adult-onset neuronal ceroid lipofuscinosis. Hum Mol Genet. 2013;22:1417-1423.
  • [Spielmeyer, 1905] Spielmeyer W. Über familiäre amaurotische Idiotien. Neurol Cb. 1905;24:620-621.
  • [Staropoli et al., 2012] Staropoli J.F., Karaa A., Lim E.T. A homozygous mutation in links neuronal ceroid lipofuscinosis to the ubiquitin-proteasome system. Am J Hum Genet. 2012;91:202-208. KCTD7
  • [Steinfeld et al., 2006] Steinfeld R., Reinhardt K., Schreiber K. Cathepsin D deficiency is associated with a human neurodegenerative disorder. Am J Hum Genet. 2006;78:988-998.
  • [Stengel, 1826] Stengel O.C. Beretnig om et maerkeligt Sygdomstilfaelde hos fire Sødskende I Nærheden af Roraas. Eyr. 1826;1:347-352.
  • [Topcu et al., 2004] Topcu M., Tan H., Yalnizoglu D. Evaluation of 36 patients from Turkey with neuronal ceroid lipofuscinosis: clinical, neurophysiological, neuroradiological and histopathologic studies. Turk J Pediatr. 2004;46:1-30.
  • [Tyynela et al., 1997] Tyynela J., Suopanki J., Santavuori P., Baumann M., Haltia M. Variant late infantile neuronal ceroid-lipofuscinosis: pathology and biochemistry. J Neuropathol Exp Neurol. 1997;56:369-375.
  • [Uvebrant and Hagberg, 1997] Uvebrant P., Hagberg B. Neuronal ceroid lipofuscinoses in Scandinavia. Epidemiology and clinical pictures. Neuropediatrics. 1997;28:6-8.
  • [Van Diggelen et al., 2001] Van Diggelen O.P., Thobois S., Tilikete C. Adult neuronal ceroid lipofuscinosis with palmitoyl-protein thioesterase deficiency: first adult-onset patients of a childhood disease. Ann Neurol. 2001;50:269-272.
  • [Vanhanen et al., 2004] Vanhanen S.L., Puranen J., Autti T. Neuroradiological findings (MRS, MRI, SPECT) in infantile neuronal ceroid-lipofuscinosis (infantile CLN1) at different stages of the disease. Neuropediatrics. 2004;35:27-35.
  • [Vesa et al., 1995] Vesa J., Hellsten E., Verkruyse L.A. Mutations in the palmitoyl protein thioesterase gene causing infantile neuronal ceroid lipofuscinosis. Nature. 1995;376:584-587.
  • [Vogt, 1905] Vogt H. Über familiäre amaurotische Idiotie und verwandte Krankheitsbilder. Monatsschr Psychiatr Neurol. 1905;18:161-171.
  • [Warrier et al., 2013] Warrier V., Vieira M., Mole S.E. Genetic basis and phenotypic correlations of the neuronal ceroid lipofusinoses. Biochim Biophys Acta. 2013;1832:1827-1830.
  • [Whiting et al., 2014] Whiting R.E., Narfström K., Yao G. Enzyme replacement therapy delays pupillary light reflex deficits in a canine model of late infantile neuronal ceroid lipofuscinosis. Exp Eye Res. 2014;125:164-172.
  • [Wisniewski et al., 1998] Wisniewski K.E., Connell F., Kaczmarski W. Palmitoyl-protein thioesterase deficiency in a novel granular variant of LINCL. Pediatr Neurol. 1998;18:119-123.
  • [Wisniewski et al., 2001] Wisniewski K.E., Zhong N., Philippart M. Pheno/genotypic correlations of neuronal ceroid lipofuscinoses. Neurology. 2001;57:576-581.
  • [Worgall et al., 2008] Worgall S., Sondhi D., Hackett N.R. Treatment of late infantile neuronal ceroid lipofuscinosis by CNS administration of a serotype 2 adeno-associated virus expressing CLN2 cDNA. Hum Gene Ther. 2008;19:463-474.